Literature DB >> 24993451

Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties.

Xing-Xing He1, An-Yuan Guo2, Chuan-Rui Xu3, Ying Chang1, Guang-Ya Xiang3, Jing Gong2, Zi-Li Dan1, De-An Tian1, Jia-Zhi Liao1, Ju-Sheng Lin1.   

Abstract

Hepatocellular carcinoma (HCC) is a worldwide malignancy; however, there is a lack of effective targeted therapies. We and others have found that miR-221 is one of the most consistently overexpressed miRNAs in liver cancer. However, the roles of miR-221 in hepatocellular carcinogenesis are still not fully elucidated. In the present study, we used bioinformatics tools, gain- and loss-of-function methods to determine the roles of miR-221 in HCC. Bioinformatics analysis showed that miR-221 is a core miRNA which targets a large number of HCC-related genes and has formed many feed-forward regulatory loops combining transcription factors (TFs) to regulate HCC-related genes. Inhibition of miR-221 in liver cancer cells decreased cell proliferation, clonogenicity, migration/invasion and also induced G1 arrest and apoptosis. In addition, we demonstrated that miR-221 bound directly to the 3'-untranslated region of BMF, BBC3 and ANGPTL2, and inhibited the expression of BMF, BBC3 and ANGPTL2. In a mouse model, lentivirus‑mediated miR-221 silencing could significantly suppress the growth of hepatoma xenografts in nude mice. In conclusion, we showed that miR-221 is a critical modulator in the HCC signaling pathway, and miR-221 silencing inhibits liver cancer malignant properties in vitro and in vivo, which may benefit the treatment for patients with unresectable HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24993451     DOI: 10.3892/or.2014.3306

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  21 in total

1.  miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF.

Authors:  Xinping Xie; Yuxiu Huang; Lihong Chen; Jinhua Wang
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

2.  Emerging role of transcription factor-microRNA-target gene feed-forward loops in cancer.

Authors:  Qian Wu; Hua Qin; Qiu Zhao; Xing-Xing He
Journal:  Biomed Rep       Date:  2015-06-11

3.  MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma.

Authors:  Hui Liu; Wenzheng Li; Changyong Chen; Yigang Pei; Xueying Long
Journal:  Tumour Biol       Date:  2015-03-25

4.  Evaluating normalization approaches for the better identification of aberrant microRNAs associated with hepatocellular carcinoma.

Authors:  Jing Shen; Qiao Wang; Irina Gurvich; Helen Remotti; Regina M Santella
Journal:  Hepatoma Res       Date:  2016-11-18

5.  miR-221 facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human bladder cancer cells by targeting STMN1.

Authors:  Jun Liu; Jian Cao; Xiaokun Zhao
Journal:  BMC Urol       Date:  2015-04-28       Impact factor: 2.264

6.  A meta-analysis of microRNA expression in liver cancer.

Authors:  Jingcheng Yang; Shuai Han; Wenwen Huang; Ting Chen; Yang Liu; Shangling Pan; Shikang Li
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

7.  Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma.

Authors:  Chuan Tian; Shanshan Yao; Li Liu; Youcheng Ding; Qingwang Ye; Xiao Dong; Yong Gao; Ning Yang; Qi Li
Journal:  Int J Mol Med       Date:  2016-11-24       Impact factor: 4.101

8.  Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues.

Authors:  Qin Tang; Qi Wang; Qiong Zhang; Sheng-Yan Lin; Yanhong Zhu; Xiangliang Yang; An-Yuan Guo
Journal:  BMC Cancer       Date:  2017-12-18       Impact factor: 4.430

Review 9.  Role of MicroRNAs-221/222 in Digestive Systems.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki
Journal:  J Clin Med       Date:  2015-08-06       Impact factor: 4.241

Review 10.  Mouse models of liver cancer: Progress and recommendations.

Authors:  Li He; De-An Tian; Pei-Yuan Li; Xing-Xing He
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.